IMMUNIC, INC. (IMUX)
CIK 1280776 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 13.6M shares as of Jul 31, 2026 (10-Q). Share count fell from 136.2M to 13.6M between Apr 16, 2026 and Apr 30, 2026, a pattern consistent with a reverse split (roughly 1-for-10); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| May2025 Pre Funded Warrants Offering | 22.9M | not tagged | — | — |
| Series A Warrants | 8.7M | $7.5 | — | — |
| May2025 Pre Funded Warrants | 8.7M | not tagged | — | — |
| Series B Warrants | 3.4M | not tagged | — | — |
| Pre Funded Warrants | 1.1M | not tagged | — | — |
| Series A Warrant and Series B Warrant | not tagged | $7.499 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 240,620 underlying shares, as reported Dec 31, 2017 (10-K).
Reported exercise price: $3719.6 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 13.9M = 13.6M O/S + 240,620 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
Reported conversion price: $1 (aggregate figure as tagged; individual notes can vary).
This filer tagged totals without per-note dimensions in its 10-Q filed Aug 11, 2026 →, so per-note terms (maturities, individual conversion prices) live in the exhibit prose and are not parsed here.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 13.6M | Jul 31, 2026 |
| + May2025 Pre Funded Warrants Offering (if exercised) | 22.9M | Jun 30, 2026 |
| + Series A Warrants (if exercised) | 8.7M | May 28, 2025 |
| + May2025 Pre Funded Warrants (if exercised) | 8.7M | Jun 30, 2026 |
| + Series B Warrants (if exercised) | 3.4M | Jun 30, 2026 |
| + Pre Funded Warrants (if exercised) | 1.1M | Jun 30, 2026 |
| Fully diluted estimate | 58.4M | +327.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $499.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full IMUX workspace